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O presente trabalho descreve as atividades antibacterianas e antifúngicas de diversas chalconas 
obtidas diretamente através da condensação aldólica tipo Claisen-Schmidt das quais se determinou 
a concentração inibitória mínima frente a diferentes microrganismos (bactérias Gram-positivas 
e Gram-negativas e fungos). Estruturas no estado sólido cristalino de sete chalconas foram 
determinadas por análise de difração de raios X (XRD). Estudos quimiométricos foram realizados 
com intuito de identificar uma potencial relação entre estrutura e atividade.
The present work describes the antibacterial and antifungal activities of several chalcones 
obtained by a straight Claisen-Schmidt aldol condensation determined by the minimal inhibitory 
concentration against different microorganisms (Gram-positive and Gram-negative bacteria and 
fungi). Solid state crystal structures of seven chalcones were determined by X-ray diffraction 
(XRD) analysis. Chemometric studies were carried out in order to identify a potential structure-
activity relationship.
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Introduction
Chalcone (1,3-diaryl-2-propen-1-ones) derivatives are 
found widespread in natural products from pteridophytes 
to highly organized multicellular organisms. This class of 
compounds is considered as key precursors for flavonoid and 
isoflavonoid syntheses1 and can be directly obtained by aldol 
reactions under basic catalytic conditions. Chemically, they 
consist of open-chain flavonoids in which the two aromatic 
rings are joined by a three-carbon α,β-unsaturated carbonyl 
system (Figure 1). Studies on their multiple biological 
activities including anti-inflammatory,2 anti-leishmania,3 
antimitotic4 and antiviral are some few examples of their 
broad range of action.5 In particular, chalcone systems 
usually show different levels of inhibition during proliferative 
processes of a plethora of cancer cell lines.6
The presence of hydroxyl, allyl and prenyl groups in 
their structures commonly potentiates their activities.7 
For instance, the inclusion of two hydroxyl groups 
(dihydroxychalcones) enhanced both the antitumor and 
lipidic antiperoxidation activities.8 Other activities have 
already been reported9-11 and Figure 2 shows some examples 
of biologically active chalcones.
Toxicity against several tumoral human cells12 renders 
this class an attractive alternative to commonly used taxoid 
compounds, which are very complex structures of low 
Figure 1. General structure of a chalcone.
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availability. Hence, the preparation and identification of 
simpler low-cost compounds such as chalcone derivatives 
for cytotoxic tests are still inexhaustible tasks aiming 
at the development of new and promising biologically 
active readily available molecules. As part of our ongoing 
studies on the synthesis, characterization and in silico 
studies of chalcone derivatives,13 it is described herein 
the preparation of 21 different chalcone derivatives, 
three of them (3c, 3f, 3u) are novel compounds, and their 
evaluation as antibacterial and antifungal agents upon 
determination of the minimal inhibitory concentration 
(MIC) against different microorganisms (Gram-positive and 
Gram-negative bacteria and fungi). Moreover, solid state 
crystal structures of seven chalcones were determined by 
X-ray diffraction (XRD) analysis. Theoretical calculation 
studies (structure modeling) were equally carried out in 
order to identify a potential structure-activity relationship.
Results and Discussion
Synthesis of chalcones
The chalcones were easily obtained from the aldol 
condensation of aromatic aldehydes and aromatic ketones14 
(Table 1), in yields ranging from 70 to 100%. Chalcones 
3a-g are derived from 3,4-methylenedioxybenzaldehyde; 
chalcones 3h-i from 4-nitrobenzaldeyde; chalcone 3J from 
4-(N,N)-dimethylbenzaldehyde; chalcones 3k-l from 
cinnamaldehyde; chalcones 3m-r from benzaldehyde and 
finally chalcones 3s-u from furfural. The chalcones were 
characterized by 1H and 13C nuclear magnetic resonance 
(NMR) spectroscopy, X-ray diffractometry and elemental 
analyses (for the novel compounds). The 1H NMR 
spectra showed two doublets between 7.0 and 8.0 ppm 
(Jtrans 15-16 Hz) confirming the trans configuration of the 
olefins whereas the carbonyl carbons appear in the range 
of 187.7 to 193.7 ppm in the 13C NMR spectra.
Due to the wide spectrum of action of this class of 
compounds and to their good cytotoxicity, our group began 
to investigate some structural modifications based on related 
studies in order to obtain molecules with potential biological 
activity. Allyl chalcones in particular were reported to exhibit 
widespread biological activities, with improved activities 
in some cases, probably due to their structural similarity to 
licochalcone E.7 In our group, studies were carried out in this 
way, and the allyl group was introduced into the structures 
of chalcones 3b, 3n and 3t. Nevertheless, the insertions were 
not efficient, not reaching the expected activity.
Biological activity
Seven bacterial strains were used for testing antimicrobial 
activities, including Gram-positives: Sthaphylococcus 
aureus ATCC 6538, Bacillus subtilis ATCC 6833, 
Streptococcus mutans ATCC 25175, Micrococcus 
luteus ATCC 10240, and Gram-negatives: Escherichia 
coli ATCC 94863, Pseudomonas aeruginosa and 
Salmonella choleraesuis ATCC 14028. Three fungi were 
used: Aspergillus niger ATCC 16404, Cladosporium 
cladosporioides IMI 178517 and Candida albicans ATCC 
18804. The results are summarized in Table 2 and indicate, 
in some cases, considerable activity against bacteria in 
comparison with the standard, especially for chalcones 
3m, 3n and 3o, which showed a good profile towards 
some microorganisms (e.g., chalcone 3n on S. mutans). 
No activity at all was observed against the following 
microorganisms: S. choleraesuis ATCC 14028, E. Coli 
ATCC 94863 and P. aeruginosa.
In some cases, the activity is dependent on the 
substituents on the aromatic ring. For instance, chalcones 
Figure 2. Some biologically active chalcone derivatives.
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3m-q, obtained from benzaldehyde, showed distinct 
activities against S. mutans (Table 2). The best activity was 
achieved when the hydroxyl group resides on the ortho 
position (as in 3n). In contrast, the activity is diminished in 
3o (OH in meta position) and in the absence of a substituent 
there was no activity. The protection of the hydroxyl group in 
3n as an allyl ether decreased the activity by two dilutions. 
Chalcones derived from furaldehyde (3s-u) were somewhat 
active but those derived from piperonal (3a-g) were inactive 
irrespective of the substituents on the aromatic ring.
When the fungi are concerned, C. cladosporioides was 
the most sensitive to the chalcones. The greatest activities 
were achieved by compounds 3a, 3e and 3k. In the last two 
cases, the activities were at the same level of dilution as 
compared to Loprox®, the standard drug used in the assay. 
Crystallographic analysis
In order to get a better insight on the relationship 
between biological activity and structures, the crystal 
structure of seven chalcones were obtained for better 
characterization. Figure 3 shows the ORTEP drawings of 
chalcones 3a, 3f, 3i, 3n, 3o, 3q and 3t and the refinement 
data are shown in the Supplementary Information section.
Principal component analysis (PCA) of chalcones
The aim of this section is to get a relationship between 
geometric and electronic properties of the 21 synthesized 
chalcones and the biological activities against S. aureus 
ATCC 6538 and C. cladosporioides IMI 178517. For 
this purpose, quantum chemical calculations were carried 
out on chalcones and analogues, as listed in Table 1. The 
chalcones were tested against 10 microorganisms, but only 
two microorganisms were selected for this study, because 
the number of active and inactive chalcones for these two 
organisms is roughly equally distributed and this is very 
important for the statistical analysis of the calculated data 
to be meaningful, as shown in Table 3.
As can be seen in Figure 3, chalcones are chemical 
compounds with several rotational degrees of freedom 
and, in turn, they present many geometric conformations 
Figure 3. ORTEP drawings of chalcones 3a, 3f, 3i, 3n, 3o, 3q and 3t, with the atom-numbering schemes. The displacement ellipsoids are drawn at the 
30% probability levels.
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Table 1. Synthesis of chalcones and analogues 3a-3u
Compound Chalcone R1 R2 R3 R4 Yield / %
3a H H H H 92
3b H OH H H 81
3c H O(allyl) H H 100
3d H H H OMe 90
3e H H H NO2 84
3f Br OH H H 80
3g H H H Ph 85
3h − − − NO2 70
3i − − − H 85
3j − − − NO2 90
3k − − − H 90
3l − − − NO2 85
3m − H H H 80
3n − OH H H 84
3o − H OH H 83
3p − H H OMe 80
3q − H H NO2 82
3r − O(allyl) H H 100
3s − − H − 96
3t − − OH − 88
3u − − O(allyl) − 100
that are energetically stable. For this reason, it is 
mandatory to carry out a conformational search to find 
the molecular conformation with the lowest energy. In 
this work, the conformational searches were carried 
out using HyperChemTM 7.5 suite of programs15 with 
semiempirical quantum method PM316,17 and random 
walk algorithm. Initially, the most active chalcone was 
analyzed and the most stable conformation was selected. 
Afterwards, the remaining chalcones were investigated and 
the energetically most stable conformation that was similar 
to the conformation selected before was chosen for the 
calculation of the molecular properties. Before calculating 
the properties, the molecular geometries were optimized 
again, but now using the density functional theory 
(DFT)18,19 with the hybrid exchange-correlation functional 
B3LYP20-22 and the basis set 6-31G(d) as implemented 
in the software package G0923, which was also used to 
calculate the molecular properties (descriptors or variables). 
In this work, the following molecular descriptors were 
calculated: HOMO-1 (second highest occupied molecular 
orbital energy), HOMO (highest occupied molecular 
orbital energy), LUMO (lowest unoccupied molecular 
orbital energy), LUMO+1 (second lowest unoccupied 
molecular orbital energy), partition coefficient (logP) (this 
property was obtained from the hydrophobic parameters 
of the substituents using HyperChemTM 7.5), Mulliken 
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3a >100 100 100 >100 >100 >100 >100 >100 >100 12.5
3b >100 >100 >100 >100 >100 >100 >100 >100 50 > 100
3c >100 50 100 100 >100 >100 >100 100 >100 > 100
3d >100 100 >100 100 >100 >100 >100 >100 100 100
3e >100 > 100 >100 >100 >100 >100 >100 >100 >100 6,3
3f >100 >100 >100 >100 >100 >100 >100 >100 100 > 100
3g >100 >100 >100 >100 >100 >100 >100 >100 >100 > 100
3h >100 >100 >100 100 >100 >100 >100 >100 >100 > 100
3i >100 >100 >100 >100 > 100 > 100 > 100 > 100 > 100 >100
3j >100 >100 >100 >100 >100 >100 >100 >100 >100 > 100
3k >100 >100 >100 >100 >100 >100 >100 100 >100 6.3
3l >100 >100 100 >100 > 100 > 100 > 100 > 100 > 100 > 100
3m >100 25 100 100 >100 >100 >100 50 >100 25
3n 100 25 25 12,5 >100 >100 >100 100 >100 25
3o 50 25 25 25 >100 >100 >100 50 100 100
3p >100 100 100 >100 >100 >100 >100 >100 >100 > 100
3q >100 >100 >100 >100 >100 >100 >100 >100 >100 > 100
3r >100 100 100 50 >100 >100 >100 >100 >100 > 100
3s >100 100 100 100 >100 >100 >100 >100 >100 50
3t 50 100 50 50 >100 >100 >100 >100 >100 100
3u > 100 50 100 50 >100 >100 >100 50 >100 > 100
Chloramphenicol 6.3 6.3 0.78 6.3 6.3 3.1 100
− − −
Loprox® − − − − − − − 6.3 12.5 6.3
Table 3. Theoretical values for the selected descriptors used in the PCA analysis for the activities against C. cladosporioides and S. aureus. The activities 
are also included
Chalcone
C. cladosporioides S. aureus
AD1,2,3,4 PsiH-13 Ref Activity b7,14 PsiL-2 A12,2,3 Activity
3a –174.90 0.00 72.64 active 0.9023 11.76 118.126 active
3b 173.37 0.00 68.50 inactive 1.1184 9.075 118.338 inactive
3c 174.92 0.00 74.32 inactive 0.8945 6.371 119.975 active
3d –175.08 0.00 88.27 active 0.9063 11.187 118.131 active
3e 176.37 0.00 74.34 active 0.9053 10.078 117.849 inactive
3f 174.09 0.00 68.57 inactive 0.8950 14.336 118.198 inactive
3g 174.07 0.00 73.34 inactive 0.9005 20.293 118.183 inactive
3h 175.27 0.00 74.20 inactive 0.8982 4.842 118.25 inactive
3i 178.39 0.02 82.50 inactive 1.0147 18.849 117.72 inactive
3j 174.69 0.00 58.69 inactive 0.9024 11.011 120.045 inactive
3k –174.43 0.00 79.11 active 0.9005 9.531 118.135 inactive
3l 174.43 0.00 60.39 inactive 0.9015 9.908 120.039 inactive
3m –175.58 0.00 79.97 active 0.8984 2.275 118.204 active
3n 177.96 0.06 81.89 active 1.1188 15.108 116.365 active
3o –179.18 0.24 97.78 active 0.8974 2.532 116.038 active
3p 178.83 0.22 82.89 inactive 0.8916 3.368 117.105 active
3q –174.68 0.00 81.53 inactive 0.8974 2.286 118.482 inactive
3r –173.97 0.05 74.20 inactive 0.9014 5.034 118.433 active
3s –175.92 0.00 88.56 active 0.8990 3.542 117.913 active
3t –179.97 0.00 75.56 active 0.8967 10.289 117.424 active
3u –175.92 0.00 66.88 inactive 0.9022 20.97 117.913 active
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electronegativity (χ = (EHOMO − ELUMO)/2), dipole moment, 
molecular polarizability, total electronic energy, heat of 
formation, electron affinity (obtained as −EHOMO), band 
gap energy (ELUMO − EHOMO), hardness, softness, molar 
refractivity index, ionization potential energy, net atomic 
charge on atom derived from electrostatic potential, 
molecular area, molecular volume, bond order, bond length 
between adjacent atoms, angles between three consecutive 
atoms, dihedral angles between four consecutive atoms, 
molecular length, hydration energy, Psi – x = Si|ci|2HOMO 
and  Psi – x = Si|ci|2LUMO, where x stands for atom number 
as shown in Figure 4.
The frontier electron reactivity theory, which explains 
many organic reactions, states that the reaction between 
two reactants takes place where the overlap of HOMO and 
LUMO is maximized.24 The HOMO density (PsiH-x) is 
closely related to the charge transfer (nucleophilic reactant), 
while for an acceptor compound the LUMO density 
(PsiL-x) is important (electrophilic reactant). A total of 
118 geometrical and electronic molecular descriptors was 
obtained from ab initio calculations in such a way that they 
can represent electronic, steric and hydrophobic features of 
the chalcones. These features are supposed to be important 
to elucidate the biological activity of the chalcones against 
S. aureus ATCC 6538 and C. cladosporioides IMI 178517.
In order to find a relationship between the calculated 
descriptors and the biological activities, an analysis using 
the multivariate statistical was carried out using the Einsight 
program.25 At the outset, the Fisher weight26 for each 
descriptor was calculated in order to discriminate those 
variables that are the most important to separate the active 
from the inactive chalcones. The Fisher weight (wk) for 
the variable k was obtained from the following equation 1:
 (1)
In this equation, –xactive and –x inactive are the mean 
values for the active and inactive molecules and 
(1/Nactive)S(xactive – –xactive)2 and (1/Ninactive)S(xinactive – –xinactive)2 
are the respective variances. Those descriptors with high 
Fisher weights are more significant to discriminate the 
compounds between active and inactive, allowing, in this 
way, a reduction in the number of variables to be used in 
PCA.
The major aim in the PCA technique is to reduce the 
dimensionality of the data set to lower dimensional space 
for analysis.27 This is achieved through an orthogonal linear 
transformation of the original data set of descriptors into a 
smaller set of uncorrelated significant principal components 
(PCs). This transformation can be seen as a rotation of 
the original coordinate system in such a way that the first 
principal component (PC1) axis describes the maximum 
variance of the data set. The second principal component 
(PC2), which is orthogonal to the first one, describes the 
second maximum variance and so on. In general, the 
great majority of the variance of the data set is described 
by the first components and can be utilized to represent 
the entire data set in a simplified way. For this reason, 
principal component analysis is a useful tool for helping in 
the visualization of hidden patterns, providing descriptive 
models. A priori, all descriptors are likewise important to 
explain the biological activity. So, before applying PCA 
technique, the data were auto-scaled, i.e., each variable 
was mean centered and divided by standard deviation, so 
each variable in the matrix data can be compared to each 
other on the same scale. The auto-scaling procedure was 
calculated according to equation 2,
 (2)
where xik represents the auto-scaled variable i for the sample 
k,  stands for standard deviation and –xi is the mean value 
of the variable i. 
Activity against C. cladosporioides IMI 178517
The atomic numbering used in the calculation of the 
molecular descriptors is shown in Figure 4. After several 
attempts to separate the active from the inactive chalcones 
against C. cladosporioides IMI 178517, the best result 
was finally obtained with three descriptors: dihedral angle 
between atoms 1, 2, 3, and 4 (DA1,2,3,4), (PsiH-13), and 
refractive index (Ref) (the names in parenthesis represent 
the names of the respective descriptors plotted in 
Figure 5). Figure 6 shows the score plots. Observe that two 
components (PC1 and PC2) are necessary to discriminate 
the chalcones into active and inactive. These two principal 
components together explain 89.33% of the total variance in 
the data set as follows: PC1 = 56.32% and PC2 = 33.01%. 
The amount of total variance explained in the data set by 
these two components represents very well the higher 
order space. The score plot in Figure 6 shows that the 
Figure 4. Atomic numbering used in the calculations of the molecular 
descriptors.
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active chalcones against C. cladosporioides are gathered 
below the solid line drawn in the figure. The mathematic 
representations for these two components are expressed 
through equations 3 and 4.
PC1 = 0.7046 Ref + 0.5552 PsiH – 13 – 0.4419DA1,2,3,4 (3)
PC2 = 0.0033 Ref + 0.6202 PsiH – 13 – 0.7845DA1,2,3,4 (4)
From analysis of equations 3 and 4, it is possible to 
see that the variable Ref is not meaningful in the second 
component but is very important in the first component. 
The other descriptors, namely PsiH-13 and dihedral angle 
between atoms 1, 2, 3, and 4 (DA1,2,3,4) are important in 
both components. For a chalcone to be classified as active 
against C. cladosporioides, it must stand below the solid 
line drawn in Figure 6. This means that the scores for both 
components should be small and, in turn, for the scores 
to be small, the variables Ref and PsiH-13 should present 
lower values. However, as shown in equations 3 and 4, 
the situation for the variable DA1,2,3,4 is a little delicate 
because it should present higher value in the first component 
(the loading is negative for this variable in PC1) and lower 
value in the second one (the loading is positive) in order 
to help in the discrimination of the compounds. As shown 
in Table 3, the value of this dihedral angle is almost 180º, 
which means that the chalcones are almost planar in this 
molecular region. PsiH-13 describes the HOMO density 
on atom 13 and, according to equations 1 and 2, it should 
have lower values in order to help in the discrimination of 
the compounds. From these observations, it is possible to 
hypothesize the three major characteristics for a chalcone to 
be active: (i) lower values of refractive index (Ref), (ii) lower 
values of the HOMO density on atom 13 (PsiH-13) (see 
Figure 4 for the numbering), and (iii) intermediate values of 
dihedral angle between the atoms 1, 2, 3 and 4 (DA1,2,3,4). 
These molecular characteristics can help us to design new 
chalcones with activity against C. cladosporioides.
Activity against S. aureus ATCC 6538
The active chalcones against S. aureus ATCC 6538 stand 
above the solid line drawn in Figure 7. As can be noted in 
this figure, only one component (PC2) is needed to separate 
the active chalcones from the inactive ones. The component 
PC2 accounts for 33.02% of the total variance of the 
original data, while the first component (PC1) accounts for 
46.62%. Both components added up to 79.64% of the total 
variance in the original data. A close look in equation 5 and 
in Figure 8 shows that the descriptors responsible for the 
discrimination are the angle between atoms 12, 2 and 3 
(A12-2-3), PsiL-2, and bond order between atoms 7 and 14 
(b7,14). Equation 5 also shows that for a compound to fall in 
the active group, it should present higher values of PsiL-2 and 
A12-2-3 variables. The bond order b7-14 is not important 
in this component, but to run the Einsight program,25 it was 
necessary to include it in the calculation.
PC1 + 0.001b7.14 + 0.694PsiL2 + 0.720A12,2,3 (5)
As pointed out before, the variable PsiL-2 is closely 
related to the importance of the atom 2 in the lowest 
unoccupied molecular orbital (LUMO). Equation 5 shows 
that this descriptor should be higher for the molecule to be 
active. That may mean that the atom 2 (Figure 4) could be 
Figure 5. Plot showing the descriptor loadings, which explain the activity 
of the compounds against C. cladosporioides. DA1,2,3,4 stands for 
dihedral angle among the atoms 1, 2, 3 and 4, PsiH-13 represents the 
HOMO density on atom 13 and Ref stands for molecular refractive index.
Figure 6. Plot showing the scores for the activity of the chalcone 
derivatives against C. cladosporioides. It is worth noting that all the active 
compounds (3a, 3d, 3e, 3k, 3m, 3n, 3o, 3s and 3t) stand below the solid 
line drawn in figure.
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involved in the formation of some kind of chemical bond in 
the structure of S. aureus ATCC 6538. From that discussion, 
it is possible to postulate that the chalcones studied need 
to present two main characteristics to express activity 
against S. aureus ATCC 6538: (i) they must have a large 
angle between atoms 12, 2 and 3 (A12,2,3), and (ii) they 
need to increase the value of LUMO density, which is 
probably related to some kind of reaction in expressing their 
activities. This characteristic can be useful in designing 
compounds with activity against S. aureus ATCC 6538.
Conclusions
A series of chalcones was prepared and evaluated 
against bacteria and fungi. Some compounds showed 
promising activity against C. cladosporioides, with 
low inhibitory values, in some cases in the same order 
of magnitude as the standard (Loprox®). Chemometric 
studies were employed to find a possible structure-activity 
relationship and allowed to establish some important 
features for the chalcones to be active. For instance, the 
best activity against C. cladosporioides IMI 178517 was 
obtained with three descriptors: dihedral angle between 
atoms, HOMO density on atom 13 (PsiH-13) and 
refractivity index (Ref) and two components (PC1 and 
PC2) were necessary to discriminate the chalcones into 
active and inactive. In the case of S. aureus ATCC 6538, 
only one component (PC2) was needed and the descriptors 
responsible for the discrimination were the bond angle 
(A12-2-3), PsiL-2, and bond order between atoms (b7,14). 
Future efforts to optimize the structures of this class of 
compounds may involve design, as well as the study of the 
effect of some groups strategically placed in positions in the 




All reagents were obtained from Sigma-Aldrich and 
used without purification. 1H NMR spectra were recorded at 
300 MHz on a Varian Mercury Plus 7.04 T spectrometer and 
chemical shifts were reported relative to internal Me4Si. 
13C NMR spectra were recorded at 75 MHz on a Varian 
Mercury Plus 7.04 T spectrometer and chemical shifts 
were reported relative to internal CDCl3. The infrared 
spectra were obtained on a Bomem MB-100 spectrometer. 
Elemental analyses were obtained on a Perkin Elmer series 
II CHNS/O Analyzer 2400.
General synthetic procedure for chalcones
The ketone (1 mmol) was added to a solution of 
NaOH (10% m/v) and ethanol (3 mL) and the mixture 
was stirred for 20 min under ice bath cooling. Then, the 
aldehyde (1 mmol) was added and the resulting mixture 
was stirred overnight at room temperature. The reaction 
mixture was acidified with 10% HCl. The precipitate was 
collected, washed with cold water, dried and purified by 
recrystallization from EtOH or in appropriate solvents 
(generally chloroform and methylene chloride). The 
chalcones that did not crystallize were washed with 
chloroform and purified by column chromatography (20% 
ethyl acetate/hexane).
Figure 7. Plot showing the scores for the activity of the compound 
derivatives against S. aureus. Note that all the active compounds stand 
above the solid line drawn in figure.
Figure 8. Graphic representation of variable loadings (A12,2,3, PsiL-2, 
b7,14) that discriminate the active from the inactive chalcones against 
S. aureus.
Silva et al. 141Vol. 24, No. 1, 2013
MIC assays
The determinations of MIC were performed essentially 
according to the National Committee for Clinical Laboratory 
Standards (NCCLS)28 as described by Ellof29 and 
Kusucu et al.30 The microorganisms were obtained from 
the Fundação Tropical de Pesquisa e Tecnologia André 
Tosello, Campinas-SP, Brazil, with exception of E. coli and 
P. aeruginosa, obtained from Departamento de Farmácia of 
Universidade Federal da Bahia, Salvador-BA, Brazil. The 
bacteria were grown for 24 h at 35 ºC on nutrient agar. The 
fungi and yeast were cultivated for 72 h at 26 ºC on malt 
extract agar and yeast malt agar, respectively. The inocula 
for the assays were prepared by cell suspensions according 
to McFarland scale 0.5 (108 CFU mL-1).
To determine MIC of the compounds against the 
microorganisms, the following modified micro dilution 
method was carried out: the compounds were dissolved 
in sterile dimethyl sulfoxide (2000 mg mL-1) and 20 µL 
of the stock solutions were transferred into 96 well sterile 
microtiter plates. Then, serial dilutions with nutrient broth 
to bacteria and malt extract broth to fungi were performed, 
so that the concentrations of the tested compounds ranged 
from 100 to 0.78 mg mL-1. Finally, an aliquot (100 µL) of 
culture medium containing the microorganism suspension 
was added to the wells. Chloramphenicol and Loprox® 
were used as the reference drugs against bacteria and 
fungi, respectively, and DMSO was used as negative 
control. The plates were incubated at 35 ºC for 24 h to 
bacteria and fungi and yeast were maintained at 26 ºC for 
72 h. After incubation, an aliquot of 50 µL of aqueous 
[3-(4,5-dimethyl-2-tiazolyl)-2,5 diphenyl-2H-tetrazolium 
bromide] (MTT at 0.05%) was added on the wells and the 
reduction of tetrazolium salt (yellow) from (blue) indicated 
the presence of viable cells. MIC is defined as the lowest 
concentration of the substances which inhibited the growth 
of the microorganisms.
Crystallographic structure determinations of compounds 
3a, 3f, 3i, 3n, 3o, 3q and 3t
Single crystal X-ray diffraction data were collected at 
room temperature using a Nonius CAD-4 diffratometer31 and 
using Cu Kα radiation (λ = 1.54180 Å). The structures were 
solved by direct methods and anisotropically refined with 
full-matrix least-squares on F2 using SHELXL97.32 The 
hydrogen atoms were placed at calculated position except 
those involved in H-bonds and weak interactions found on 
difference maps and refined with riding constraints. With 
regard to the hydrogen atoms, those bonded to carbon 
atoms were placed in expected positions according to the 
stereochemical predictions. They were refined with fixed 
individual displacement parameters 20% greater than 
the equivalent isotropic displacement parameter of the 
corresponding carbon atom. Aromatic C-H bond distances 
were fixed according to the riding model (0.93 Å). The (x, y, 
z) fractional coordinates and the isotropic thermal parameter 
of these H atoms were not constrained during refinements. 
The Mercury33 and ORTEP-334 programs were used within 
the WinGX35 software package to deal with the processed 
crystallographic data and artwork representations. The 
conformational and geometric features of this molecule 
were checked comparing with other similar structures. 
The crystallographic data for compounds 3f, 3i, 3a, 3n 
and 3t were deposited at the Cambridge Crystallographic 
Data Center under the numbers 819655, 819656, 819657, 
819681 and 823762, respectively.
The respective solutions, anisotropic refinements, 
geometrical calculations, molecular packing and drawings 
were performed using the program package WINGX. (3a): 
C16H12O3, a = 7.809(2), b = 11.1764(9), c = 28.601(2) Å, 
orthorhombic system, space group Pcab, R = 0.0557; (3f): 
C16H11O4Br, a = 4.160(3), b = 11.757(2), c = 27.598(7) Å, 
β = 92.87(4)o , monoclinic system, space group P21/c, 
R = 0.0809; (3i): C15H11NO3, a = 4.7580(9), b = 6.096(1), 
c = 10.658(2) Å, α = 95.807(2)o, β = 90.482(2)o, 
γ = 96.397(2)o, triclinic system, space group P1, 
R = 0.0492; (3t): C13H10O3, a = 3.9530(9), b = 14.583(2), 
c = 17.893(5) Å, monoclinic, space group P21/n, 
R = 0.0527; (3o): C15H12O2: a = 12.641(1), b = 12.066(2), 
c = 7.813(1) Å, β = 101.278(9)o, monoclinic system, space 
group P21/c, R = 0.0820; (3n): C15H12O2, a = 6.822(2), 
b = 10.474(4), c = 17.097(2) Å, α = 73.88(2), β = 84.29(2), 
γ = 87.66(3)o. Triclinic, space group P-1, R = 0.0701; (3q): 
C15H11NO3, a = 6.299(3), b = 13.226(3), c = 14.809 Å, 
β = 99.73(9)o , monoclinic system, space group P21/c, 
R = 0.0660.
Spectroscopic data for the chalcones
(2E)-3-(1,3-Benzodioxol-5-yl)-1-phenylprop-2-en-1-one 
(3a):36 IR (KBr) νmax/cm-1 3021, 2928, 1660, 1598, 1503, 
1310, 1104, 770, 686; 1H NMR (300 MHz, CDCl3) 8.02-
7.98 (m, 2H), 7.73 (d, 1H, J 15.7 Hz), 7.61-7.46 (m, 3H), 
7.36 (d, 1H, J 15.7 Hz), 7.16 (d, 1H, J 1.4 Hz), 7.11 (dd, 
1H, J 8.1 and 1.9 Hz), 6.84 (d, 1H, J 8.1 Hz), 6.02 (s, 2H); 
13C NMR (75 MHz, CDCl3) 190.4, 149.9, 148.4, 144.7, 
138.3, 132.6, 129.3, 128.5, 128.4, 125.2, 120.0, 108.6, 
106.6, 101.6.
(E)-3-(Benzo[d][1,3]dioxol-6-yl)-1-(2-hydroxyphenyl)
prop-2-en-1-one (3b):36 1H NMR (300 MHz, CDCl3) 12.90 
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(s, 1H), 7.90 (dd, 1H, J 6.6 and 1.4 Hz), 7.85 (d, 1H, 
J 15.3 Hz), 7.50 (d, 1H, J 15.3 Hz), 7.52-7.47 (m, 1H), 7.18 
(dd, 1H, J 6.9 and 1.7 Hz), 7.14 (d, 1H, J 1.45 Hz), 7.03 
(dd, 1H, J 8.4 and 0.9 Hz), 6.97-6.91 (m, 1H), 6.82 (d, 1H, 
J 8.1 Hz), 6.05 (s, 2H); 13C NMR (75 MHz, CDCl3) 193.5, 
163.5, 150.3, 148.5, 145.3, 136.2, 129.5, 129.0, 125.7, 
120.0, 118.8, 118.6, 117.9, 108.7, 106.7, 101.7.
(E)-1-(2-(allyloxy)phenyl)-3-(benzo[d][1,3]dioxol-6-yl)
prop-2-en-1-one (3c): 1H NMR (300 MHz, CDCl3) 7.64 
(dd, 1H, J 7.4 and 1.8 Hz), 7.56 (d, 1H, J 15.7 Hz), 7.47-
7.41 (m, 1H), 7.30 (d, 1H, J 15.7 Hz), 7.09-6.96 (m, 4H), 
6.81 (d, 1H, J 7.8 Hz), 6.10-5.97 (m, 3H), 5.42 (dq, 1H, 
J 3.0 and 1.5 Hz), 5.26 (dq, 1H, J 3.0 and 1.5 Hz); 13C NMR 
(75 MHz, CDCl3) 192.5, 157.0, 149.5, 148.2, 142.6, 132.7, 
132.5, 130.4, 129.7, 129.5, 125.2, 124. 9, 120.9, 117.6, 
112.8, 108.5, 106.5, 101.5, 69.2 anal. calcd. for C16H14O3: C, 
75.57; H, 5.55; O,18.88; found: C, 75.48; H, 5.51; O, 19.01.
(E)-3-(Benzo[d][1,3]dioxol-6-yl)-1-(4-methoxyphenyl) 
prop-2-en-1-one (3d):36 1H NMR (300 MHz, CDCl3) 
7.99-8.05 (m, 2H), 7.73 (d, 1H, J 15.6 Hz), 7.38 (d, 1H, 
J 15.9 Hz), 7.17 (d, 1H, J 1.9 Hz), 7.11 (dd, 1H, J 8.4 and 
1.9 Hz), 6.95-7.00 (m, 1H), 6.83 (d, 2H, J 7.8 Hz), 6.02 
(s, 2H), 3.88 (s, 3H); 13C NMR (75 MHz, CDCl3) 188.5, 
163.3, 149.7, 148.3, 143.8, 131.2, 130.7, 129.5, 125.0, 
119.9, 113.8, 108.6, 106.6, 101.6, 55.5.
(E)-3-(Benzo[d][1,3]dioxol-6-yl)-1-(4-nitrophenyl)prop-
2-en-1-one (3e):36 1H NMR (300 MHz, CDCl3) 8.37-8.32 
(m, 2H), 8.15-8.11 (m, 2H), 7.78 (d, 1H, J 15.4 Hz), 7.31 (d, 
1H, J 15.4 Hz), 7.18-7.13 (m, 2H), 6.88 (d, 1H, J 8.1 Hz), 
6.06 (s, 2H); 13C NMR (75 MHz, CDCl3) 188.8, 150.7, 
150.6, 148.6, 146.7, 143.3, 129.3, 128.8, 126.0, 123.9, 
119.2, 108.8, 106.7, 101.8.
(E)-3-(4-Bromobenzo[d][1,3]dioxol-5-yl)-1-(2-hydroxy-
phenyl) prop-2-en-1-one (3f): 1H NMR (300 MHz, CDCl3) 
12.80 (s, 1H), 8.23 (d, 1H, J 15.6 Hz), 7.88 (dd, 1H, 
J 8.1 and 1.7 Hz), 7.53-7.47 (m, 1H), 7.44 (d, J 15.6 Hz), 
7.23 (s, 1H), 7.10 (s, 1H), 7.03 (dd, 1H, J 8.1 and 1.7 Hz), 
6.97-6.91 (m, 1H), 6.06 (s, 2H); 13C NMR (75 MHz, 
CDCl3) 193.3, 163.6, 150.6, 148.0, 143.7, 136.4, 129.6, 
127.9, 120.7, 119.9, 118.9, 118.7, 113.4, 106.5, 102.4. 
Anal. Calcd. for  C16H11BrO4: C, 55.36; H, 3.19. Found: 
C, 55,25; H, 3.16.
(E)-3-(Benzo[d][1,3]dioxol-6-yl)-1-(4-phenyl)prop-2-en-
1-one (3g):37 1H NMR (300 MHz, CDCl3) 8.11-8.08 (m, 
2H), 7.78 (d, 1H, J 15.7 Hz), 7.74-7.64 (m, 4H), 7.51-7.38 
(m, 3H), 7.43 (d, J 15.7 Hz, 1H), 7.20 (d, 1H, J 1.8 Hz), 
7.15 (dd, 1H, J 8.0 and 1.4 Hz), 6.85 (d, 1H, J 8.0 Hz), 6,03 
(s, 2H); 13C NMR (75 MHz, CDCl3) 189.7, 149.9, 148.4, 
145.4, 144.6, 139.9, 137.0, 129.4, 129.0, 128.9, 128.1, 
127.3, 127.2, 125,3, 119.9, 108.7, 106.7, 101.6.
(E)-1,3-bis(4-nitrophenyl)prop-2-en-1-one (3h):38 
1H NMR (300 MHz, CDCl3) 8.41-8.37 (m, 1H), 8.34-8.28 
(m, 3H), 8.21-8.16 (m, 2H), 7.91-7.81 (m, 3H), 7.61 (d, 
1H, J 15.5 Hz); 13C NMR (75 MHz, CDCl3) 188.2, 143.4, 
142.2, 140.3, 129.5, 129.4, 129.2, 124.7, 124.3, 124.2, 
124.0, 123.8.
(2E)-3-(4-Nitrophenyl)-1-phenylprop-2-en-1-one (3i):39 
1H NMR (300 MHz, CDCl3) 8.30-8.25 (m, 2H), 8.06-
8.02 (m, 2H), 7.85-7.75 (m, 3H), 7.82 (d, 1H, J 15.6 Hz); 
13C NMR (75 MHz, CDCl3) 189.6, 148.5, 141.4, 141.0, 
137.4, 133.3, 128.9, 128.8, 128.5, 125.6, 124.1.
(E)-3-(4-(Dimethylamino)phenyl)-1-(4-nitrophenyl)prop-
2-en-1-one (3j):40 1H NMR (300 MHz, CDCl3) 8.38-8.31 
(m, 2H), 8.15-8.09 (m, 2H), 7.82 (d, 1H, J 15.3 Hz), 7.58-
7.54 (m, 2H), 7.27 (d, 1H, J 15.3 Hz), 6.73-6.69 (m, 2H); 
13C NMR (75 MHz, CDCl3) 188.9, 152.3, 149.6, 147.8, 
144.2, 130.9, 129.1, 123.7, 122.2, 116.0, 111.9, 40.2.
(2E,4E)-1,5-Diphenylpenta-2,4-dien-1-one (3k):41 IR 
(film) νmax/cm-1 3059, 3027, 1676, 1594, 1448, 1034, 776, 
700; 1H NMR (300 MHz, CDCl3) 8.03-7.93 (m, 2H), 7.63-
7.22 (m, 10H), 7.13-6.92 (m, 2H); 13C NMR (75 MHz, 
CDCl3) 190.3, 144.7, 141.8, 138.1, 135.9, 132.5, 129.1, 
129.0, 128.8, 128.7, 128.5, 128.4, 128.3, 127.2, 126.8, 125.2.
(2E,4E)-1-(4-Nitrophenyl)-5-phenylpenta-2,4-dien-
1-one (3l):41 1H NMR (300 MHz, CDCl3) 8.36-8.32 (m, 
2H), 8.12-8.08 (m, 2H), 7.66 (dd, 1H, J 8.8 and 1.5 Hz), 
7.54-7.50 (m, 2H), 7.43-7.35 (m, 3H), 7.07-7.02 (m, 3H); 
13C NMR (75 MHz, CDCl3) 188.9, 149.9, 146.7, 143.6, 
143.1, 135.7, 129.7, 129.3, 128.9, 128.6, 127.5, 126.5, 
124.5, 123.8, 123.5.
(2E)-1,3-Diphenylprop-2-en-1-one (3m):42 IR (KBr) 
3056, 1661, 1605, 1576, 1448, 746, 689 cm–1. 1H NMR 
(300 MHz, CDCl3) 8.01-7.97 (m, 2H), 7.77 (d, 1H, 
J 15.9 Hz), 7.55-7.24 (m, 9H); 13C NMR (75 MHz, CDCl3) 
189.5, 144.1, 137.6, 134.3, 132.3, 130.0, 128.4, 128.1, 
128.0, 128.0, 121.4.
(E)-1-(2-Hydroxyphenyl)-3-phenylprop-2-en-1-one 
(3n):43 1H NMR (300 MHz, CDCl3) 12.82 (s, 1H), 7.95-7.91 
(m, 2H), 7.69-7.64 (m, 3H), 7.54-7.43 (m, 3H), 7.05-6.93 
(m, 2H); 13C NMR (75 MHz, CDCl3) 193.7, 163.6, 145.5, 
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136.4, 134.6, 130.9, 129.6, 129.0, 128.7, 120.1, 118.8, 
118.6.
(E)-1-(3-Hydroxyphenyl)-3-phenylprop-2-en-1-one 
(3o):43 1H NMR (300 MHz, DMSO-d6): 9.89 (s, 1H), 
7.92-7.85 (m, 3H), 7.75 (d, 1H, J 15.6 Hz), 7.65 (dd, 1H, 
J 1.5 and 1.1 Hz), 7.50-7.38 (m, 5H), 7.09 (dd, 1H, J 2.6 and 
0.9 Hz); 13C NMR (75 MHz, CDCl3) 189.5, 169.3, 150.9, 
145.5, 139.6, 134.7, 130.7, 129.7, 129.0, 128.5, 126.1, 
125.9, 121.7, 121.7.
(E)-1-(4-Methoxyphenyl)-3-phenylprop-2-en-1-one 
(3p):39 1H NMR (300 MHz, CDCl3) 8.07-8.02 (m, 2H), 
7.80 (d, 1H, J 15.7 Hz), 7.66-7.63 (m, 2H), 7.55 (d, 1H, 
J 15.7 Hz), 7.43-7.39 (m, 3H), 7.00-6.96 (m, 2H), 3.88 
(s, 3H); 13C NMR (75 MHz, CDCl3) 188.7, 163.4, 143.9, 
135.0, 131.0, 130.8, 130.3, 128.9, 128.3, 121.8, 113.8, 
55.4.
(E)-1-(4-Nitrophenyl)-3-phenylprop-2-en-1-one (3q):39 
1H NMR (300 MHz, CDCl3) 8.37-8.32 (m, 2H), 8.17-8.12 
(m, 2H), 7.85 (d, 1H, J 15.6 Hz), 7.69-7.63 (m, 2H), 7.49 
(d, 1H, J 15.6 Hz), 7.47-7.43 (m, 3H); 13C NMR (75 MHz, 
CDCl3) 189.0, 150.0, 146.8, 143.0, 134.2, 131.2, 129.4, 
129.1, 128.7, 123.8, 121.2.
(E)-1-(2-(Allyloxy)phenyl)-3-phenylprop-2-en-1-one 
(3r):44 1H NMR (300 MHz, CDCl3) 7.68-7.64 (m, 1H), 7.63-
7.56 (m, 2H), 7.49-7.43 (m, 2H), 7.41-7.36 (m, 3H), 7.05 
(td, 1H, J 7.5 and 1.4 Hz), 6.98 (dd, 1H, J 8.2 and 0.7 Hz), 
6.10-5.97 (m, 1H), 5.42 (dq, 1H, J 2.8 and 1.4 Hz), 5.24 
(dq, 1H, J 2.8 and 1.4 Hz), 4.64 (dt, 3H, J 3.2 and 1.4 Hz); 
13C NMR (75 MHz, CDCl3) 192.7, 157.1, 142.7, 135.0, 
132.9, 132.5, 130.5, 130.1, 129.5, 128.8, 128.3, 127.1, 
120.9, 117.7, 112.8, 69.2.
(2E)-3-(2-Furyl)-1-phenylprop-2-en-1-one (3s):45 IR 
(film) νmax/cm-1 3129, 3067, 1663, 1603, 1552, 1223, 1013, 
971, 884, 776; 1H NMR (300 MHz, CDCl3) 8.04-7.99 (m, 
2H), 7.58 (d, 1H, J 15.4 Hz), 7.58-7.51 (m, 1H), 7.50-7.42 
(m, 4H), 7.44 (d, 1H, J 15.4 Hz); 13C NMR (75 MHz, 
CDCl3) 189.8, 151.6, 144.9, 132.7, 130.7, 128.5, 128.4, 
119.2, 116.3, 112.6.
(2E)-3-(2-Furyl)-1-(3-hydroxyphenyl)prop-2-en-1-one 
(3t):45 IR (KBr) νmax/cm-1 3261, 3128, 1647, 1595, 1551, 
1276, 1022, 980, 777; 1H NMR (300 MHz, CDCl3) 7.87 (d, 
J 7.8 Hz; 1H), 7.73 (t, 1H, J 2.2 Hz), 7.58 (d, 1H, J 15.1 Hz), 
7.52-7.47 (m, 2H), 7.37 (d, 1H, J 15.1 Hz), 7.35-7.28 (m, 
1H), 6.71 (d, 1H, J 3.4 Hz), 6.49 (dd, 1H, J 3.4 and 1.9 Hz), 
2.33 (s, 3H); 13C NMR (75 MHz, CDCl3) 189.30, 169.26, 
150.81, 145.34, 142.31, 139.59, 135.94, 129.58, 129.28, 
128.82, 128.48, 127.29, 126.74, 124.97, 121,55. 125.86, 
125.68, 21.06
(E)-1-(3-(Allyloxy)phenyl)-3-(furan-2-yl)prop-2-en-1-one 
(3u): 1H NMR (300 MHz, CDCl3) 7.63-7.52 (m, 4H), 7.45-
7.36 (m, 2H), 7.12 (dd, 1H, J 2.6 and 0.7 Hz), 6.71 (d, 1H, 
J 3.4 Hz), 6.50 (dd, 1H, J 3.4 and 1.9 Hz), 6.14-6.01 (m, 
1H), 5.44 (dq, 1H, J 3.1 and 1.5 Hz), 5.31 (dq, 1H, J 3.1 and 
1.5 Hz), 4.61 (dt, 2H, J 3.1 and 1.5 Hz); 13C NMR (75 MHz, 
CDCl3) 189.2, 158.7, 151.5, 144.8, 139.3, 132.7, 130.5, 
129.4, 120.9, 119.7, 119.1, 117.8, 116.2, 113.5, 112.6, 
68.7; anal. calcd. for C19H16O4: C, 74.01; H, 5.23; O, 20.76; 
found: C, 73.93; H, 5.19; O, 20.88.
Supplementary Information
Data spectra and spectra of synthesized compounds are 
available free of charge at http://jbcs.sbq.org.br as PDF file.
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